FDA and CBD: No Pain Relief Anytime Soon for Industry

Author Michael A. Walsh The FDA held a “stakeholders” call on May 25 to present information on how it reached its present stance concerning CBD and to answer a few questions. FDA’s presentation included its assessment of survey data concluding that the predominant uses of CBD are ingestion resulting in multiple adverse health effects. Based […]

Go to Source

Powered by WPeMatico